- This medicine contains the active ingredient adalimumab, a medicine that affects your body’s immune system (the body’s own defense system).
- Intended for the treatment of the following inflammatory diseases:
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Arthritis associated with enthesitis
- Ankylosing spondylitis
- Axial spondyloarthritis, in which ossification is not yet detected on radiographs.
- Psoriatic arthritis
- Plaque psoriasis
- Hidradenitis suppurativa (acne inverse)
- Crohn’s disease
- Ulcerative colitis
- Non-infectious uveitis
- The active ingredient of the drug adalimumab is a human monoclonal antibody. Monoclonal antibodies are proteins that attach to a specific target.
- The target of adalimumab is the protein tumor necrosis factor-alpha (TNFa). TNFa is involved in the body’s defense reactions. In the diseases mentioned above, the amount of TNFα increases. This medicine attaches to TNFa and thereby reduces inflammatory processes in these diseases.
IDACIO 40 mg/0,8 ml Injekt.-Lösung i.e.Fertigspr.(adalimumab),6
€4,508.23
IDACIO belongs to the group of drugs for the treatment of tumors and has an effect on the immune system.
Descripción
Información adicional
| Peso | 0.10 kg |
|---|---|
| Producing country | |
| Manufacturer |
Abacus Medicine A/S |
| Dosage form | |
| Usage | |
| Package | |
| EAN |
Ap-16227711 |
Shipping & Delivery
